Literature DB >> 2938356

Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine.

D W Dreesen, K W Bernard, R A Parker, A J Deutsch, J Brown.   

Abstract

Following a routine 0.1 ml booster dose of Merieux rabies human diploid cell vaccine (HDCV), administered intradermally, 23(10.2%) of 226 persons had signs and symptoms compatible with an immune complex-like disease. The disease had its onset from 3-13 days after the injection, lasted 1-5 days, and consisted primarily of urticaria (78.3%), macular rash (65.2%), angiooedema (39.1%), and arthralgia (17.4%). None of the cases were considered severe, and all recovered with no sequelae. There were significant differences in attack rates between men (78.3% of all cases) and women, and between those receiving vaccinations on different days. Similar reactions have been reported following intramuscular booster doses of HDCV. Since the Merieux HDCV is used worldwide, physicians administering HDCV must be aware of these adverse reactions and warn patients. Appropriate therapy should be instituted as warranted by severity of reactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938356     DOI: 10.1016/0264-410x(86)90096-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  [Rabies: epidemiology, pre- and postexposure immunization].

Authors:  Herwig Kollaritsch; Wolfgang Maurer
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

2.  Dog bites in Bosnia.

Authors:  A Croft; R Archer
Journal:  Br J Gen Pract       Date:  1997-07       Impact factor: 5.386

3.  A decision-analytic approach to postexposure rabies prophylaxis.

Authors:  S B Cantor; R D Clover; R F Thompson
Journal:  Am J Public Health       Date:  1994-07       Impact factor: 9.308

Review 4.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.